This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Alecensa®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek®▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib) Great Britain
      • ALECENSA® (alectinib) Northern Ireland
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin) Great Britain
      • Polivy®▼(polatuzumab vedotin) Northern Ireland
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • Alecensa®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek®▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib) Great Britain
        • ALECENSA® (alectinib) Northern Ireland
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin) Great Britain
        • Polivy®▼(polatuzumab vedotin) Northern Ireland
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq® (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    HEMLIBRA

     

     

    For routine prophylaxis of bleeding episodes in patients of all ages with congenital haemophilia A, classified as severe or with Factor VIII (FVIII) inhibitors

    • HEMLIBRA®▼ (emicizumab)
    • Efficacy
      • Efficacy RCTs
      • Efficacy Non-RCTs
      • Study Designs
    • Safety
    • UK Experience
    • Congresses
      • ASH 2021 and EAHAD 2022
    • More
      • Efficacy
      • Safety
      • UK Experience
      • Congresses

    You are here:

    1. Roche Medicines
    2. Rare Diseases
    3. HEMLIBRA®▼ (emicizumab)
    4. Congresses

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

    Untitled Document

    Prescribing Information Great Britain
    Prescribing Information Northern Ireland



    Adverse event reporting and additional monitoring


    EXPERTS discuss HEMLIBRA Global congresses and symposia

    Expert perspectives on HEMLIBRA and the future of haemophilia A care

    The latest from global congresses and symposia, where experts from around the world have highlighted the challenges faced by people with haemophilia A. With the advent of modern therapies, such as HEMLIBRA, we are seeing a shift in focus towards improving all aspects of patients’ lives, beyond bleed protection.

    Hear healthcare professionals discuss the future of haemophilia A care, share first-hand treatment experience with HEMLIBRA, present patient case studies and explore data findings.


    Featured

    ASH 2021

    ASH 2021 and EAHAD 2022

    HEMLIBRA highlights from the latest American Society of Hematology (ASH) and European Association for Haemophilia and Allied Disorders (EAHAD) congresses.

    View digital summaries of surgical experience with HEMLIBRA, data on use of HEMLIBRA in older patients with comorbidities and the updated safety evaluation of HEMLIBRA prophylaxis.

    ASH 2021 and EAHAD 2022


    HEMLIBRA highlights

    ISTH 2021

    HEMLIBRA highlights from the latest International Society on Thrombosis and Haemostasis (ISTH) Congress. Learn how HEMLIBRA is helping patients with severe haemophilia A achieve the ‘zero bleeds milestone'. View real-world case studies, expert analyses and clinical findings in this collection of posters and video presentations.

    ISTH 2021

    EAHAD 2021

    HEMLIBRA highlights from the latest European Association for Haemophilia and Allied Disorders (EAHAD) Congress.

    EAHAD 2021

    Experts Uncut

    Hear from healthcare professionals about their perspectives on haemophilia A patient care and management in the UK.

    Experts Uncut


    ASH, American Society of Hematology; EAHAD, European Association for Haemophilia and Allied Disorders; FVIII, Factor VIII; ISTH, International Society on Thrombosis and Haemostasis; MHRA, Medicines and Healthcare products Regulatory Agency.

    M-GB-00006898
    Date of preparation: May 2022

    ROCHE LOGO , CHUGAI LOGO

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 01.07.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    This is a promotional website intended for UK healthcare professionals, designed, built and funded by Roche Products Ltd. This website is intended to be viewed on a desktop/laptop. M-GB-00008047 Date of Preparation June 2022.